Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Boehringer, Cornell target the lung

by Michael McCoy
February 20, 2017 | A version of this story appeared in Volume 95, Issue 8

Boehringer Ingelheim and Weill Cornell Medicine are joining to discover new approaches to treating chronic obstructive pulmonary disease. The three-year collaboration is intended to combine Weill Cornell’s understanding of chronic airway diseases with Boehringer’s expertise in discovering therapies for respiratory disease. The two organizations earlier collaborated on inflammatory bowel disease.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.